CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)	B-cell neoplasm, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 1	2026-07-13		NCT03774654

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Baylor College of Medicine	267
Center for Cell and Gene Therapy, Baylor College of Medicine	40
National Cancer Institute (NCI)	3015
The Methodist Hospital Research Institute	124

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Houston Methodist Hospital	Houston	United States	260
Texas Children's Hospital	Houston	United States	187